Source: Abstract #PS-097 Sustained virological response for 94% of people treated with low-cost, legally imported generic direct acting antivirals for hepatitis C: analysis of 1087 patients in 4 treatment programmes—J. Freeman, et al.
Study Aims and Results: Direct-acting antivirals (DAAs) are extremely expensive in most countries, and the cost has created a barrier to treatment for those with hepatitis C virus (HCV). This study evaluated the efficacy of generic sofosbuvir (SOF), ledipasvir (LDV), and daclatasvir (DCV) obtained from India, Bangladesh, Egypt and China. Data were obtained from 1,087 patients undergoing treatment in hospitals, private doctors and clinics in 42 countries worldwide. Treatment length, choice of DAA, and use of ribavirin (RBV) were based on HCV genotype and fibrosis level. Response rates (SVR12) for patients taking SOF/RBV = 91%; SOF/LDV +/- RBV = 92%; SOF/DCV = 86%.
Conclusion: HCV treatment using equivalent generic medications is a feasible, economic treatment choice, especially when considering limited access to non-generics.
Editorial Comments: James Freeman and colleagues provide an excellent, evidence-based service to the hepatitis C community. Note that the generics provided in this study have been quality tested. I strongly suggest avoiding the purchase of generic drugs from any source that has not been properly vetted.
To read the entire June HCV Advocate newsletter, click hereShare This Page